

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2022

Commission File Number 001-38370

**CollPlant Biotechnologies Ltd.**

(Exact name of registrant as specified in its charter)

**4 Oppenheimer St, Weizmann Science Park  
Rehovot 7670104, Israel**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

---

CollPlant Biotechnologies Ltd. has posted to its website an updated corporate presentation. A copy of the presentation is furnished with this Report of Foreign Private Issuer on Form 6-K as [Exhibit 99.1](#) and is incorporated herein by reference.

---

1

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**COLLPLANT BIOTECHNOLOGIES LTD.**

Date: August 26, 2022

By: /s/ Eran Rotem

Name: Eran Rotem

Title: Deputy CEO and Chief Financial Officer

---

2

## CollPlant Overview



August 2022

## Safe harbor statement

Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and are expected to be affected by a variety of risks and factors that are beyond our control. Risks and uncertainties for our company include, but are not limited to: the Company's history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based Bioink and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based Bioink and medical aesthetics products including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected

capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. Many of these factors that will determine actual results are beyond our ability to control or predict. For a discussion of the factors that may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, see the "Risk Factors" section of included in our most recently filed Annual Report on Form 20-F. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward-looking statements contained in this presentation to reflect subsequent information, events, results or circumstances or otherwise. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

# CollPlant – Unlocking the Regenerative Potential of rhCollagen



## Regenerative and Aesthetic Medicine Company

Developing innovative technologies and products for tissue regeneration and organ manufacturing, to help people live longer and better



## Proprietary Plant-based Technology Platform

Only commercially viable solution for mass production of rhCollagen



## Collaboration Agreements with Industry Leaders

- AbbVie (ABBV)- Worldwide exclusive agreement for dermal and soft tissue fillers. Up to \$103mm in payments plus royalties.
- 3D Systems (DDD)- Bioprinted solutions for breast reconstruction treatments



## Well Capitalized



\$36M in cash  
Zero debt  
(June 30, 2022)

3



## Plant-based platform produces human collagen in mass-scale

### Expressing 5 human genes



4





## rhCollagen- The ideal building block for regenerative medicine


Clear advantages over tissue-extracted collagen



Better bio-functionality



Superior homogeneity



Improved safety and greater purity

5

### Plant-derived



### Animal Extracted



Cell binding domains

CollPlant  
Pioneering Regenerative Medicine

## Product Pipeline

### Aesthetic medicine

Dermal/soft tissue fillers



Collaboration with



Photocurable dermal filler

### Regenerative medicine

3D bioprinted products



Breast implants



Regenerative Tissue Matrix for breast reconstruction



BioInk formulations



Soft and hard tissues

### Personalized medicine

Tissue Models




Gut-on-a-chip

6

CollPlant  
Pioneering Regenerative Medicine

# Dermal/Soft Tissue Fillers

In collaboration with  **Allergan**  
an AbbVie company



## Dermal fillers market overview



**~2.6 M**  
HA procedures  
in 2020 in the US<sup>1</sup>




**\$5B, 9.6% CAGR**  
Global dermal filler market,  
2021, CAGR 2022-2028<sup>2</sup>



**\$100-\$250/unit**  
Cost per syringe<sup>3</sup>

2020 Procedure breakdown, U.S (by material)<sup>1</sup>



## Collaboration agreement with AbbVie

### Agreement highlights:



A worldwide exclusive development and commercialization agreement for dermal and soft tissue fillers for the medical aesthetics market



Combines CollPlant's proprietary rhCollagen technology and AbbVie's technology



Right of first negotiation for exclusive rights to use the rhCollagen for the commercialization and sale of an injectable breast implant and photocurable dermal filler products

### Financial highlights:



Up to \$103M in potential payments, including:

- \$14M upfront payment
- Up to \$89M milestones and option payments



Royalties on products sales



CollPlant will manufacture and sell to AbbVie the rhCollagen used in the products

9



## rhCollagen-based photocurable regenerative dermal filler\* key attributes

**Easy injection  
(30G needle)**



**Injection**

**Sculpting before  
curing**



**Sculpting**

**Optimized post  
curing stiffness**



**Photocuring in-situ**

**Good tissue  
retention**



**Tissue regeneration**

*\*AbbVie's Option Product*

10 <http://collplant.com/products/photocurable-dermal-filler-animation-video/>








## 3D Bioprinted Tissues and Organs



3D bioprinting represents a wide range of development opportunities



## rhCollagen-based BioInks enable high resolution printing of elastic scaffolds



13

CollPlant  
Printing Regenerative Medicine

**Breast  
Reconstruction /  
Augmentation**





## Breast implants market overview

Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it.



**\$2.5B Market**  
worldwide (2021)<sup>1</sup>




**\$ 5-10K Cost**  
per full procedure in US<sup>2</sup>



**~2,200,000**  
Breast implant procedures WW (2020)<sup>3</sup>  
~400,000 in US (2020)<sup>4</sup>



**FDA alert:** Patients with breast implants have an increased risk of developing breast implant Associated-Anaplastic Large Cell Lymphoma (Feb 2019)<sup>5</sup>



- <https://www.imaragroup.com/breast-implant-market>
- <https://www.webmd.com/beauty/cosmetic-procedures/breast-augmentation/>
- [https://www.fda.gov/oc/oc-content/uploads/2022/01/ISAPS-Global-Survey\\_2020.pdf](https://www.fda.gov/oc/oc-content/uploads/2022/01/ISAPS-Global-Survey_2020.pdf)
- <https://www.plasticsurgery.org/documents/News/Statistics/2020/plastic-surgery-statistics-full-report-2020.pdf>
- <https://www.fda.gov/medical-devices/letters-health-care-providers/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-ald-letter-health-care-providers>




15

## CollPlant's 3D bioprinted regenerative breast implants for aesthetic and reconstructive procedures



Breast scaffold bioprinting



rhCollagen + ECM components



Implantation and vascularization



Implant degrades over time and replaced by newly formed tissue

16 \* Pig study initiated in Q2 2022, expected to conclude in six months



## Regenerative Tissue Matrix (RTM) Developed in collaboration with 3D Systems



Provide extra coverage, direct-to-implant reconstruction and superior cosmetic results



US: mostly human-sourced (93%)  
EU: mostly animal-sourced



Used in 61% of U.S. breast reconstruction surgeries



Breast reconstruction procedures using ADMS /yr (US): **60K**



Market potential (US) **\$600Mn**

Surgical matrixes derived from cadavers and animals are associated with high costs, supply shortage and batch-to-batch variability

rhCollagen-based regenerative tissue matrix



17



## rhCollagen BioInk compositions in development



18





## rhCollagen-bioink platform for biofabrication



Animal-free, excellent safety profile



Optimal rheology at room temperature



Supports high viability of different cell types



Biocompatible, non immunogenic

Additional bioinks coming soon:



19

## Our Partners

### Companies



Supply agreement



Collaboration agreement



Development and commercialization agreement



Joint development agreement

### Consortiums & organizations



Scalable manufacturing of tissue engineered products



Universal BioInk



Industry committee

20



## Experienced management team



**Yehiel Tal**  
**CEO**  
Regentis Biomaterials  
ProChon Biotech  
Kulicke & Soffa Industries



**Eran Rotem**  
**Deputy CEO & CFO**  
Tefron, CFO (NYSE, TASE)  
Healthcare Tech., CFO  
(NASDAQ) & Gamida  
E&Y



**Michal Roytman**  
**VP Sales & Marketing**  
Ocon Medical  
Neuroderm (now Mitsubishi Tanabe)  
Neurim Pharmaceuticals  
Frutarom (now IFF)



**Ilana Belzer, PhD**  
**COO**  
BioHarvest  
Procognia Ltd.  
Omrix Biopharmaceuticals  
Interpharm



**Philippe Bensimon, PharmD**  
**VP RA/QA/CA**  
Maquet Getinge  
3M Medical



**Hadas Dreiher-Horowitz**  
**VP HR**  
Elbit  
Teva Pharmaceuticals  
Mul-T-Lock

21



## CollPlant investment thesis



Only commercially viable technology currently available that can produce truly human collagen



Multi-billion dollar markets: innovative rhCollagen products initially aimed at 3D bioprinting and medical aesthetics



Broadly applicable technology: Ideal building block/scaffolding molecule for regenerative medicine



Strategic agreement with AbbVie and 3D Systems



Clinically validated technology



Proven management team

22



**Thank you**



**CollPlant**  
Biotechnologies

Pioneering  
Regenerative  
Medicine